Last reviewed · How we verify
Benepali
At a glance
| Generic name | Benepali |
|---|---|
| Also known as | Etanercept |
| Sponsor | University of Leeds |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis (PHASE3)
- Observational Study to Evaluate the Real-Life Effectiveness of Benepali Following Transition From Enbrel
- RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid Arthritis
- Targeted Treatment Early With Etanercept + Methotrexate vs.T2T Care for DMARD-naïve Early RA Patients Based on naïve T-cell Stratification (PHASE4)
- Benepali® PEN Patient Satisfaction Survey
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Benepali CI brief — competitive landscape report
- Benepali updates RSS · CI watch RSS
- University of Leeds portfolio CI